Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-A-1041 Monotherapy and Combination in HER2-Positive Advanced Solid Tumors
NCT04487236Phase 1Completed
- Sponsor
- Suzhou Zanrong Pharmaceutical Technology Co. Ltd.
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZN-A-1041 in solid tumor and breast cancer (11 arms), sponsored by Suzhou Zanrong Pharmaceutical Technology Co. Ltd. Primary endpoints: The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1a at 23 days, The safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1b at 21 days and 1 more. Started Oct 2020; status: completed.
02
Drugs
ZN-A-1041
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT04487236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487236.